MedTrace Logo

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

NCT04468061 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-04-29

No results posted yet for this study

Summary

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative.

The names of the study interventions involved in this study are:

* Sacituzumab govitecan (Trodelvy™;IMMU-132)
* Pembrolizumab (Keytruda®; MK-3475)

Conditions

Interventions

DRUG

Sacituzumab Govitecan

Intravenous Infusion

DRUG

Pembrolizumab

Intravenous Infusion

Sponsors & Collaborators

Principal Investigators

  • Ana C Garrido-Castro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2027-04-01
Completion
2029-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04468061 on ClinicalTrials.gov